Matthew Hamilton Rosenberg’s Quest Diagnostics DGX Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.3K	Hold	110	–	–	﹤0.01%	541
2026 Q1	$21.6K	Hold	110	–	–	﹤0.01%	537
2025 Q4	$19.1K	Sell	110 -2	-2%	-$364	﹤0.01%	551
2025 Q3	$21.3K	Hold	112	–	–	﹤0.01%	532
2025 Q2	$20.1K	Hold	112	–	–	﹤0.01%	560
2025 Q1	$18.9K	Buy	112 +32	+40%	+$5.26K	﹤0.01%	542
2024 Q4	$12.1K	Hold	80	–	–	﹤0.01%	604
2024 Q3	$12.4K	Buy	80 +39	+95%	+$5.82K	﹤0.01%	588
2024 Q2	$5.62K	Sell	41 -39	-49%	-$5.34K	﹤0.01%	647
2024 Q1	$10.8K	Hold	80	–	–	﹤0.01%	599
2023 Q4	$11K	Buy	80 +39	+95%	+$5.13K	﹤0.01%	598
2023 Q3	$5K	Hold	41	–	–	﹤0.01%	684
2023 Q2	$5.76K	Hold	41	–	–	﹤0.01%	677
2023 Q1	$5.8K	Hold	41	–	–	﹤0.01%	719
2022 Q4	$6.41K	Hold	41	–	–	﹤0.01%	704
2022 Q3	$5K	Buy	+41	New	+$5.4K	﹤0.01%	708

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Matthew Hamilton Rosenberg's DGX Position: Q2 2026 in Review

Matthew Hamilton Rosenberg held its Quest Diagnostics (DGX) position steady in Q2 2026 at 110 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #541.

Matthew Hamilton Rosenberg first reported a position in DGX in Q3 2022 and has held it in 16 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Matthew Hamilton Rosenberg held 110 shares of Quest Diagnostics worth $23.3K as of Q2 2026.
Matthew Hamilton Rosenberg left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up ﹤0.01% of Matthew Hamilton Rosenberg's portfolio in Q2 2026, its #541 holding.
Matthew Hamilton Rosenberg first reported a position in Quest Diagnostics in Q3 2022 and has held it in 16 quarters since.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Matthew Hamilton Rosenberg's 13F filing for Q2 2026, filed 17 Jul 2026.